The bacteriological and clinical efficacy of gemifloxacin in CAP studies against MDR strains of S. pneumoniae,
including ciprofloxacin-intermediate and ciprofloxacin-resistant clinical isolates, showed a high level of bacterial
eradication
These observations would appear to corroborate clinically some of the in vitro data, indicating the dual targeting activity
of gemifloxacin against pneumococci